Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CN201 in adult precursor B-cell acute lymphoblastic leukemia
ChiCTR2200064470Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CN201 in acute lymphoblastic leukemia (ALL) (4 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall frequency and severity of adverse events, Incidence of dose-limiting toxicities and 2 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
CN201
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2200064470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064470.